Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy

Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma

(2021) Karina Biserova et al.   Cells

Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs

(2020) Xin Yi Wong et al.   ACS Nano

Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer

(2020) Danielle M. Valcourt et al.   ACS Nano

Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy

(2020) Yanjie Liu et al.   NANO LETTERS

Albumin-Based Nanotheranostic Probe with Hypoxia Alleviating Potentiates Synchronous Multimodal Imaging and Phototherapy for Glioma

(2020) Zhenzhen Yang et al.   ACS Nano

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

(2020) Yonghan He et al.   Nature Communications

Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma

(2020) Derek Reichel et al.   ACS Nano

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma

(2020) Enyuan Shang et al.   Cancers

Development of Mcl-1 inhibitors for cancer therapy

(2020) Arvind Negi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates

(2020) Mahwash Mukhtar et al.   Chemosensors

Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins

(2019) Rumani Singh et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

BCL-2 family isoforms in apoptosis and cancer

(2019) Chloe F. A. Warren et al.   Cell Death & Disease

Recent advances in the development of Mcl-1 inhibitors for cancer therapy

(2019) Alexander W. Hird et al.   PHARMACOLOGY & THERAPEUTICS

Challenges to curing primary brain tumours

(2019) Kenneth Aldape et al.   Nature Reviews Clinical Oncology

Clinical cancer nanomedicine

(2019) Joy Wolfram et al.   Nano Today

Bcl‐2/Bcl‐xL inhibition predominantly synergistically enhances the anti‐neoplastic activity of a low‐dose CUSP9 repurposed drug regime against glioblastoma

(2019) Marc‐Eric Halatsch et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma

(2019) Cyril Neftel et al.   CELL

Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals High Safety and Potency against Human Glioblastoma in Mice

(2019) Huazhen Qin et al.   MOLECULAR PHARMACEUTICS

Antitumor Activity of a Binary EGFR/DNA Targeting Strategy Overcomes Resistance of Glioblastoma Stem cells to Temozolomide

(2019) Zeinab Sharifi et al.   CLINICAL CANCER RESEARCH

Red Blood Cell Membrane Processing for Biomedical Applications

(2019) Luigia Rossi et al.   Frontiers in Physiology

Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents

(2018) Yichao Wan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma

(2018) Yiru Zhang et al.   Scientific Reports

Primary brain tumours in adults

(2018) Sarah Lapointe et al.   LANCET

Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma

(2018) Yu Jiang et al.   ACS Nano

Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

(2018) Yan Zou et al.   ADVANCED MATERIALS

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma

(2017) Georg Karpel-Massler et al.   Expert Opinion on Drug Discovery

Overcoming therapeutic resistance in glioblastoma: the way forward

(2017) Satoru Osuka et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

(2017) T-C Teh et al.   LEUKEMIA

Intra-tumor heterogeneity from a cancer stem cell perspective

(2017) Pramudita R. Prasetyanti et al.   Molecular Cancer

Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

(2017) Nai-Jia Huang et al.   Nature Communications

Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL

(2017) Georg Karpel-Massler et al.   Nature Communications

Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications

(2017) Silvia Anahi Valdés-Rives et al.   Biomed Research International

Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors

(2016) Yi Zhu et al.   AGING CELL

Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo

(2016) Georg Karpel-Massler et al.   Oncotarget

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study

(2015) Mathilde Hunault-Berger et al.   AMERICAN JOURNAL OF HEMATOLOGY

The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update

(2015) Waseem Ahmad Siddiqui et al.   ARCHIVES OF TOXICOLOGY

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

(2015) Thomas J. Kipps et al.   LEUKEMIA & LYMPHOMA

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

(2015) Y. Xiao et al.   MOLECULAR CANCER THERAPEUTICS

Principles of nanoparticle design for overcoming biological barriers to drug delivery

(2015) Elvin Blanco et al.   NATURE BIOTECHNOLOGY

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD

(2014) Fresia Pareja et al.   MOLECULAR CANCER RESEARCH

Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity

(2014) D Schmid et al.   Cell Death & Disease

Apoptosis and Molecular Targeting Therapy in Cancer

(2014) Mohamed Hassan et al.   Biomed Research International

Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles

(2013) Ronnie H. Fang et al.   Nanoscale

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

(2013) Peter E. Czabotar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier

(2013) D. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metabolism of Nanomaterials in Vivo: Blood Circulation and Organ Clearance

(2012) Bing Wang et al.   ACCOUNTS OF CHEMICAL RESEARCH

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Bcl-2 family proteins and caspases in the regulation of apoptosis

(2011) Mohammad Shamsul Ola et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

(2011) C.-M. J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization

(2010) O. Jameel Shah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

(2009) M. H. Kang et al.   CLINICAL CANCER RESEARCH

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Anti-Apoptosis Mechanisms in Malignant Gliomas

(2008) David S. Ziegler et al.   JOURNAL OF CLINICAL ONCOLOGY

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

(2008) K E Tagscherer et al.   ONCOGENE